Consonance-Hfw Acq Corp (SRZN) Stock Price, Quote & News

Company Profile

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 489 9000

Website: www.surrozen.com

Address:

171 Oyster Point Boulevard, Suite 400, South San Francisco, United States

BuyoutBobby May. 13 at 2:11 PM

$SRZN something interesting regarding Regeneron. They removed REGN7041 from their pipeline on May 6 which was the last day of ARVO. The drug was in a trial against Uveitis and recruitment was ongoing from January until April. They wanted to recruit 72 people for it and primary completion of the trial is showing as June 2028. Seems like the trial was stopped and the drug discontinued. Surrozen has SZN-8143 potentially against Uveitis so that is very interesting. https://clinicaltrials.gov/study/NCT07218770

1 · Reply

BuyoutBobby May. 13 at 6:48 AM

$SRZN i asked myself did it ever happen before that TCG and TCGX invest in the same company? And yes it did at Carmot Therapeutics Rapt Therapeutics TCG and TCGX were both shareholders of these companies when they were sold to big pharma. So the pattern seems to be TCG invests early and helps to build the company and TCGX joins when the company is more advanced and ready for the exit.

0 · Reply

BuyoutBobby May. 12 at 7:38 PM

$SRZN can you remember that i was surprised that Michael Lauw has 2 full time positions? He worked at Surrozen and Lineage Cell Therapeutics at the same time. That is even more interesting because Lineage works very closely in a cooperation with Roche on a ophthalmology drug. When TCG started to prepare Surrozen for a buyout with the related party deal termination in October 2025 Michael Lauw's position at Lineage could have been a problem for Surrozen because of potential conflicts with his close work with Roche. So it seems like he was replaced at Lineage and promoted at Surrozen. October he was still VP, February 2026 only consultant and April Lineage hired a new person for clinical development in April.

0 · Reply

vu_jade May. 12 at 6:24 PM

$SRZN great chart

0 · Reply

BuyoutBobby May. 12 at 11:10 AM

$SRZN we always think about Surrozen as a preclinical company but SZN-043 could still be there waiting for somebody to continue the development. Even if not the data of SZN-043 is valuable and makes Surrozen more than a preclinical company.

0 · Reply

BuyoutBobby May. 11 at 8:43 PM

$SRZN i looked at the investor presentation of Surrozen from 2025 compared to the current version. In 2026 they deleted SZN-113 and all preclinical data of it. They also deleted the preclinical data of SZN-8143. Then they deleted this picture which showed what the WNT pathway could treat. Maybe too similar to what Boehringer Ingelheim wants? Anyway the behavior fits to a company that wants to keep some information private to be able to show it to interested companies in the VDR to increase auction dynamics and value creation.

0 · Reply

BuyoutBobby May. 11 at 12:08 PM

$SRZN @Jw242 @raticals is that a potential explanation why Surrozen/TCG are preparing everything for the best possible auction in 2026?

1 · Reply

BuyoutBobby May. 10 at 10:58 AM

$SRZN this is an article from 2023 and they are writing about our WNT drug. We already have that drug in preclinical stage. It only takes a big pharma company to continue the work on it. If they don't do it as fast as possible then somebody else will do it. https://med.stanford.edu/news/insights/2023/06/restoring-the-blood-brain-barrier.html

1 · Reply

WallStreetBuyDip May. 9 at 12:42 PM

$MRAM vs $SRZN comparing two trending tickers

0 · Reply

BuyoutBobby May. 9 at 8:13 AM

$SRZN another reason why i think a pre-IND buyout makes sense is that Surrozen could be much more than just a ophthalmology company. Their drugs and technology platforms could be used to make treatments against a huge amount of diseases. Surrozen doesn't have the ability to do that but a big pharma company could start/continue Surrozen's work on: Stroke / ischemic brain injury Alzheimer’s disease Multiple sclerosis Traumatic brain injury Epilepsy Hearing loss / cochlear hair-cell regeneration Idiopathic pulmonary fibrosis / IPF Pulmonary hypertension Wound healing Diabetic wound healing Type 1 diabetes Type 2 diabetes Pancreas regeneration / beta-cell regeneration Kidney disease Focal segmental glomerulosclerosis / FSGS Liver disease Severe alcohol-associated hepatitis Bone fracture healing Muscle atrophy Cancer / oncology

1 · Reply

Surrozen to Present at Upcoming Healthcare Investor Conference

2026-05-07T11:30:10.000Z - 6 days ago

Surrozen price target raised to $44 from $36 at H.C. Wainwright

2026-05-07T01:00:24.000Z - 6 days ago

Surrozen reports Q1 EPS ($11.65) vs. ($7.43) last year

May 6, 2026, 4:05 PM EDT - 7 days ago

Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update

2026-04-29T22:03:27.000Z - 13 days ago

Surrozen management to meet with Cantor

Apr 28, 2026, 4:05 PM EDT - 15 days ago

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-04-21T09:41:40.000Z - 22 days ago

Surrozen initiated with a Buy at TD Cowen

2026-03-24T10:15:11.000Z - 7 weeks ago

Surrozen price target raised to $36 from $32 at H.C. Wainwright

2026-03-23T21:30:13.000Z - 7 weeks ago

Surrozen files $200M mixed securities shelf

Mar 23, 2026, 4:05 PM EDT - 7 weeks ago

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 4, 2026, 1:10 PM EST - 2 months ago

Surrozen Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-19T11:15:51.000Z - 2 months ago

Surrozen initiated with an Overweight at Cantor Fitzgerald

Feb 12, 2026, 1:30 PM EST - 3 months ago

Surrozen Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Dec 3, 2025, 3:25 PM EST - 5 months ago

Surrozen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 9:30 AM EST - 5 months ago

Surrozen Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 4:05 PM EST - 6 months ago

Surrozen to Present at Upcoming Healthcare Investor Conferences

2025-11-13T11:15:34.000Z - 6 months ago

Surrozen initiated with an Outperform at LifeSci Capital

Nov 12, 2025, 9:30 AM EST - 6 months ago

Surrozen Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-07T21:20:19.000Z - 6 months ago

Surrozen names Andrew Maleki as CFO

Nov 7, 2025, 4:05 PM EST - 6 months ago

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

Sep 10, 2025, 11:30 AM EDT - 8 months ago

Surrozen Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 4:15 PM EDT - 8 months ago

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 4, 2025, 8:00 AM EDT - 8 months ago

Surrozen Transcript: Cantor Global Healthcare Conference 2025

Aug 13, 2025, 7:00 AM EDT - 9 months ago

Surrozen Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 8, 2025, 4:05 PM EDT - 9 months ago

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

2025-05-20T20:35:11.000Z - 1 year ago

Surrozen files $150M mixed securities shelf

2025-05-14T12:37:05.000Z - 1 year ago

Surrozen granted patent from USPTO directed to antibody-based molecules

May 14, 2025, 8:30 AM EDT - 1 year ago

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 9, 2025, 4:05 PM EDT - 1 year ago

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

2025-04-23T20:29:24.000Z - 1 year ago

Surrozen files to sell 5.21M shares of common stock for holders

2025-03-31T20:40:11.000Z - 1 year ago

Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

2025-03-25T19:46:37.000Z - 1 year ago

Surrozen to focus Wnt expertise, technologies on ophthalmology programs

2025-03-25T19:46:20.000Z - 1 year ago

Surrozen to discontinue development of SZN-043 in alcohol associated hepatitis

Mar 24, 2025, 9:00 AM EDT - 1 year ago

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

2025-01-30T11:05:29.000Z - 1 year ago

Surrozen initiated with a Buy at H.C. Wainwright

2025-01-03T12:15:21.000Z - 1 year ago

Guggenheim upgrades Surrozen to Buy after ‘encouraging’ SZN-043 data

2025-01-03T11:20:31.000Z - 1 year ago

Surrozen upgraded to Buy from Neutral at Guggenheim

Nov 19, 2024, 2:25 PM EST - 1 year ago

Surrozen Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 3:00 PM EST - 1 year ago

Surrozen Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 6, 2024, 9:00 AM EST - 1 year ago

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Nov 4, 2024, 8:30 AM EST - 1 year ago

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Jun 12, 2024, 8:30 AM EDT - 2 years ago

Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Jun 10, 2024, 8:30 AM EDT - 2 years ago

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Jun 4, 2024, 8:30 AM EDT - 2 years ago

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

May 9, 2024, 8:30 AM EDT - 2 years ago

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 8, 2024, 4:05 PM EDT - 2 years ago

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Apr 3, 2024, 8:40 AM EDT - 2 years ago

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Apr 1, 2024, 8:30 AM EDT - 2 years ago

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Apr 1, 2024, 8:30 AM EDT - 2 years ago

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Jan 18, 2024, 8:30 AM EST - 2 years ago

Surrozen Provides Corporate Update on Clinical Programs

Nov 8, 2023, 4:05 PM EST - 2 years ago

Surrozen Provides Third Quarter 2023 Financial Results

Aug 9, 2023, 4:05 PM EDT - 3 years ago

Surrozen Provides Second Quarter 2023 Financial Results

Jun 5, 2023, 8:30 AM EDT - 3 years ago

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

May 10, 2023, 4:05 PM EDT - 3 years ago

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

Apr 5, 2023, 8:30 AM EDT - 3 years ago

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Mar 22, 2023, 4:30 PM EDT - 3 years ago

Surrozen Earnings Call Transcript: Q4 2022

Mar 22, 2023, 4:01 PM EDT - 3 years ago

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Mar 20, 2023, 4:30 PM EDT - 3 years ago

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Jan 4, 2023, 4:41 PM EST - 3 years ago

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 14, 2022, 4:30 PM EST - 3 years ago

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Oct 10, 2022, 8:00 AM EDT - 3 years ago

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

Sep 26, 2022, 8:00 AM EDT - 3 years ago

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Aug 11, 2022, 8:00 AM EDT - 4 years ago

Surrozen Reports Second Quarter 2022 Financial Results

Jun 13, 2022, 8:00 AM EDT - 4 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

May 24, 2022, 8:00 AM EDT - 4 years ago

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

May 18, 2022, 8:00 AM EDT - 4 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

May 16, 2022, 8:00 AM EDT - 4 years ago

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

May 11, 2022, 8:00 AM EDT - 4 years ago

Surrozen Reports First Quarter 2022 Financial Results

May 5, 2022, 8:00 AM EDT - 4 years ago

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

May 2, 2022, 8:00 AM EDT - 4 years ago

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Mar 24, 2022, 8:00 AM EDT - 4 years ago

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

Jan 10, 2022, 8:00 AM EST - 4 years ago

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Jan 5, 2022, 8:00 AM EST - 4 years ago

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Nov 15, 2021, 4:00 PM EST - 4 years ago

Surrozen Reports Third Quarter 2021 Financial Results

Nov 15, 2021, 8:00 AM EST - 4 years ago

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

BuyoutBobby May. 13 at 2:11 PM

1 · Reply

BuyoutBobby May. 13 at 6:48 AM

0 · Reply

BuyoutBobby May. 12 at 7:38 PM

0 · Reply

vu_jade May. 12 at 6:24 PM

$SRZN great chart

0 · Reply

BuyoutBobby May. 12 at 11:10 AM

0 · Reply

BuyoutBobby May. 11 at 8:43 PM

0 · Reply

BuyoutBobby May. 11 at 12:08 PM

$SRZN @Jw242 @raticals is that a potential explanation why Surrozen/TCG are preparing everything for the best possible auction in 2026?

1 · Reply

BuyoutBobby May. 10 at 10:58 AM

1 · Reply

WallStreetBuyDip May. 9 at 12:42 PM

$MRAM vs $SRZN comparing two trending tickers

0 · Reply

BuyoutBobby May. 9 at 8:13 AM

1 · Reply

Quantumup May. 8 at 7:24 PM

BofA reiterated Top Pick $OCUL Buy; $27 in its SMID cap investor's guide to Health Care (including top stock ideas) $EYPT REGN FDMT RHHBY KOD $SRZN Here's what BofA said in its note: https://x.com/Quantumup1/status/2052831264231526811?s=20

0 · Reply

BuyoutBobby May. 8 at 6:34 PM

$SRZN seems like ARVO was a good conference for Surrozen. They were able to show their Eylea(aflibercept) combination drugs to a lot of their peers in ophthalmology. And they got a lot of interest from strategics at their poster presentation. We know one company that as a huge reason to be interested(Regeneron). Eylea is still one of their biggest money makers but the patent of aflibercept expired already or will expire soon. EyleaHD got kinda new patents so they still want to make money with that. But it is just a higher dose of aflibercept. That means Surrozen can take their normal aflibercept and make combination drugs with it. Then technically we will have Eylea combination drugs which is very weird and dangerous for Regeneron especially if another big pharma company acquirers Surrozen.

1 · Reply

BuyoutBobby May. 7 at 2:17 PM

$SRZN that is an interesting information from the 10Q. Somebody used the opional closing option to get shares of the second tranche shares in December 2025. But nobody did it in Q1 while the share price was higher. How is that possible? Seems like a good deal to get shares for $11.6 and then sell them for more than $20. While TCG/TCGX are loading up expensive shares with open market buys or even through the ATM. I have an idea why nobody did it in Q1 but more about that tomorrow when ARVO is done.

1 · Reply

Quantumup May. 7 at 12:36 PM

Guggenheim reiterated its Top Pick $EYPT Buy; $68 $OCUL $SRZN REGN RHHBY FDMT KOD Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2052365956958109965?s=20

1 · Reply

BuyoutBobby May. 6 at 8:51 PM

$SRZN interesting timing to publish the 10Q while they are at the ARVO meeting. https://www.sec.gov/Archives/edgar/data/1824893/000119312526209179/srzn-20260331.htm

1 · Reply

BuyoutBobby May. 6 at 1:29 PM

$SRZN seems like i was right regarding ARVO and aflibercept. Surrozen published that SZN-8141 uses aflibercept and good preclinical data for it. What do you think could happen now that Regeneron knows that we are developing Eylea combination drugs and that we openly publish this on big ophthalmology conferences while Boehringer Ingelheim is very interested in these drugs? While BI is also working with Re-Vana on sustained release drugs. That means the threat of a big pharma competitor getting sustained release Eylea combination drugs is real.

1 · Reply

BuyoutBobby May. 6 at 12:23 PM

$SRZN Bayer buys another ophthalmology company. Interesting that validates the sector as something where big pharma is willing to spend money for and pressures the other big players to make a move too. https://www.bayer.com/media/en-us/bayer-to-acquire-perfuse-therapeutics-to-complement-ophthalmology-pipeline/

0 · Reply

BillionerOfKing May. 5 at 6:21 PM

$SRZN Current Stock Price: $32.42

0 · Reply

BuyoutBobby May. 4 at 5:34 AM

$SRZN another buyout with TCG involvement. Candid Therapeutics was acquired yesterday by UCB. They had the plan to make an IPO but then agreed to the buyout instead.

0 · Reply

BuyoutBobby May. 1 at 9:14 PM

$SRZN i found an older video from the Eyecelerator event in May 2025. There Re-Vana published which drugs they were working on. Kinda interesting especially if you take that information and the potential conclusion from it. If Re-Vana worked with Regeneron and Roche on sustained release versions of their drugs since early 2025 then what is that information doing to a company like Boehringer Ingelheim? And what is it doing to a company that owns potentially superior biology(Surrozen)? We were able to watch since May 2025 what this has done to Surrozen and we know how it could end.

0 · Reply

BuyoutBobby Apr. 30 at 10:42 PM

$SRZN was that the reason why Shao Lee Lin left the board of Surrozen? Interesting. https://www.globenewswire.com/news-release/2026/04/30/3285473/0/en/cue-biopharma-names-shao-lee-lin-m-d-ph-d-ceo-president-and-board-director-to-lead-continued-growth-and-transformation-into-a-clinical-stage-company.html

1 · Reply

BuyoutBobby Apr. 28 at 2:54 PM

$SRZN Surrozen will present some data of SZN-8141 at ARVO/Eyecelerator event. Will they now "reveal" on the big stage that 8141/8143 use the aflibercept sequence so they are kinda Eylea combinations? Its one thing putting that information in your investor presentation but to publish it at a conference could trigger more action from Regeneron for example. If TCG/Surrozen think that they are ready for it then they could do it.

1 · Reply

Market Cap	336.34M
Revenue (ttm)	3.48M
Net Income (ttm)	-242.03M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,954.89%
Debt to Equity Ratio	0.00

Volume	68,405
Avg Vol	110,880
Day's Range	N/A - N/A
Shares Out	11.49M
Stochastic %K	33%
Beta	0.59
Analysts	Strong Sell
Price Target	$42.50